A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD 1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies

Trial Profile

A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD 1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Cemiplimab (Primary) ; Carboplatin; Cyclophosphamides; Docetaxel
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 13 Dec 2017 According to a Sanofi media release, updated results will be submitted for presentation at a 2018 medical congress.
    • 17 Nov 2017 Last checked against ClinicalTrials.gov record.
    • 09 Nov 2017 Planned End Date changed from 1 Jul 2019 to 20 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top